[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiaobo Yang, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100482704",false,"NCT05565495","The Effects of ECMO on the Pharmacokinetics of Hydromorphone","Inclusion Criteria:\n\n* Between the ages of 18 and 80;\n* Using hydromorphone for pain relief;\n* Using ECMO for more than 96h\n\nExclusion Criteria:\n\n* Allergic to hydromorphone;\n* Use of CRRT during ECMO;\n* Liver function Child-Pugh B, C grade;\n* Pregnancy;\n* Intestinal obstruction;\n* Refused to sign the informed consent.","ALL","18 Years","80 Years",{"count":18,"type":19},26,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.",[25],"Extracorporeal Membrane Oxygenation",[25,27,28],"Pharmacokinetics","Hydromorphone","RECRUITING","2024-08-05",{"date":32,"type":33},"2024-08-06","ACTUAL",{"date":35,"type":33},"2022-01-01",{"date":37,"type":19},"2024-09-01",{"name":39,"class":40},"Xiaobo Yang, MD","OTHER",""]